Liraglutide: The GLP-1 That Started It All

The current GLP-1 era is dominated by semaglutide and tirzepatide, but the playbook they follow was largely written by liraglutide. As the first GLP-1 receptor agonist to see broad use — first for type 2 diabetes and later, at a higher dose, for weight management — it established both the promise and the practical realities that newer drugs would refine. Understanding liraglutide is a good way to understand how the whole category actually works.

What liraglutide established

Liraglutide is a once-daily injectable that mimics GLP-1, an incretin hormone the gut releases after eating. By engaging GLP-1 receptors, it enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on appetite centers in the brain to reduce hunger. The combined effect is better blood sugar control and, importantly, weight loss as a consequence rather than a side note.

That last point reshaped the field. For years, diabetes drugs that caused weight gain were the norm. A medication that improved glycemic control and reduced weight pointed toward treating obesity as a metabolic, hormonally regulated condition rather than a failure of willpower. Tray, breakfast, muesli — illustrating Liraglutide: The GLP-1 That Started It All

In the 56-week SCALE Obesity and Prediabetes trial (NEJM, 2015), 63.2% of people on liraglutide 3.0 mg lost at least 5% of body weight versus 27.1% on placebo — proof that targeting GLP-1 produced clinically meaningful weight loss in people without diabetes.

Where it sits against newer drugs

Blueberries, berries, fruits — illustrating Liraglutide: The GLP-1 That Started It All

Honesty about effect size matters here. In SCALE, the 3,731 participants on liraglutide 3.0 mg lost a mean of about 8 kg, versus roughly 2.8 kg on placebo. That is genuinely useful — but smaller than what semaglutide and tirzepatide later delivered, and liraglutide requires a daily injection where the newer agents are weekly.

Drug	Trial	Mean weight loss	Dosing
Liraglutide 3.0 mg	SCALE (2015)	~8% (vs ~2.6% placebo)	Once daily
Semaglutide 2.4 mg	STEP 1 (2021)	14.9% (vs 2.4% placebo)	Once weekly
Tirzepatide 15 mg	SURMOUNT-1 (2022)	up to ~22.5%	Once weekly

Why it still matters

Liraglutide didn’t just precede the heavyweights; it de-risked them. In the LEADER trial (NEJM, 2016), liraglutide reduced major adverse cardiovascular events by 13% and cardiovascular death by 22% in 9,340 people with type 2 diabetes at high cardiovascular risk — early outcome evidence that helped build confidence in the class. The titration approach to managing nausea and the framing of obesity as treatable physiology also trace back through this drug. It remains a legitimate option, particularly where its specific dosing or availability fits a patient better than the alternatives.

The takeaway

Liraglutide is the GLP-1 that proved the idea. It is no longer the most potent option, and for many people seeking maximal weight loss it has been superseded. But its effects are real, its safety record is substantial, and its historical role is hard to overstate. When you see the dramatic numbers from newer drugs, it’s worth remembering they were built on the foundation this one laid — and that “first and foundational” is different from “best for every goal today.”